公开(公告)号：US20200297770A1

公开(公告)日：2020-09-24

申请号：US16881572

申请日：2020-05-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200261506A1

公开(公告)日：2020-08-20

申请号：US16833187

申请日：2020-03-27

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  C07K16/28 ,  A61K39/395 ,  C07K16/24 ,  A61K39/12 ,  A61K39/00 ,  C12N5/0783 ,  A61K45/06 ,  A61P35/02 ,  C07K14/47 ,  A61K38/08 ,  C07K14/54 ,  C07K7/06 ,  A61K39/39 ,  A61P35/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200222465A1

公开(公告)日：2020-07-16

申请号：US16833175

申请日：2020-03-27

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200206268A1

公开(公告)日：2020-07-02

申请号：US16814508

申请日：2020-03-10

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  C07K14/54 ,  C07K7/06 ,  C07K16/28 ,  A61K39/39 ,  A61P35/00 ,  C07K14/47 ,  A61K38/08 ,  A61K39/395 ,  C07K16/24 ,  A61K39/12 ,  A61K39/00 ,  C12N5/0783 ,  A61K45/06 ,  A61P35/02

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200085873A1

公开(公告)日：2020-03-19

申请号：US16692035

申请日：2019-11-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  C07K16/24 ,  A61K39/00 ,  C07K14/47 ,  C07K16/28 ,  A61K39/12 ,  C07K14/54 ,  C07K7/06 ,  A61P35/02 ,  A61P35/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/395 ,  A61K39/39 ,  A61K38/08

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190255110A1

公开(公告)日：2019-08-22

申请号：US16274505

申请日：2019-02-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/02 ,  A61K39/00 ,  A61K39/39 ,  A61K39/12 ,  C07K16/28 ,  C07K16/24

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240374642A1

公开(公告)日：2024-11-14

申请号：US18606710

申请日：2024-03-15

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240269183A1

公开(公告)日：2024-08-15

申请号：US18606662

申请日：2024-03-15

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/4748 ,  C12N5/0636

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240245723A1

公开(公告)日：2024-07-25

申请号：US18585158

申请日：2024-02-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/4748 ,  C12N5/0636

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230263830A1

公开(公告)日：2023-08-24

申请号：US18173159

申请日：2023-02-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61K38/08 ,  A61K39/12 ,  A61K39/39 ,  A61K39/001102 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/5434 ,  C07K16/244 ,  C07K16/2818 ,  C07K16/2821 ,  C12N5/0636 ,  A61K45/05 ,  A61K2039/5156

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.